

EXPRESS MAIL CERTIFICATE

Date \_\_\_\_\_ Label No. \_\_\_\_\_  
I hereby certify that, on the date indicated above, this paper or  
fee was deposited with the U.S. Postal Service & that it was  
addressed for delivery to the Assistant Commissioner for  
Patents, Washington, DC 20231 by "Express Mail Post Office to  
Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR  
CREDIT ANY EXCESS IN THE FEES DUE WITH THIS  
DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

\_\_\_\_\_  
Name (Print)

\_\_\_\_\_  
Signature

Customer No.:



07278

PATENT TRADEMARK OFFICE

Docket No.: 1034/1J800US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: St. George-Hyslop et al.

Serial No.: 09/884,629

Confirmation No.: 3866

Filed: 6/29/01

For: TRANSGENIC ANIMAL MODEL OF NEURODEGENERATIVE  
DISORDERS

-----  
INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of  
Patents and Trademarks  
Washington, DC 20231

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy  
of Form PTO-1449 and copies of the documents listed thereon.

In accordance with MPEP Sections 609 and 707.05(b), it is requested

that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

This submission is filed before a first Office Action on the merits of the application has been received.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.


It is believed that no fee is due. However, if the Commissioner determines that a fee is due, the Commissioner is hereby authorized to charge the

above deposit account for any deficiency.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: November 26, 2001

A handwritten signature in black ink, appearing to read "Paul F. Fehlner", written over a horizontal line.

Paul F. Fehlner, Ph.D.

Registration No. 35,135

Attorney for Applicant(s)

DARBY & DARBY  
805 Third Avenue  
New York, NY 10022  
(212) 527-7700

**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

DOCKET NO.: 1034/1J800US1 SERIAL NO: 09/884,629  
APPLICANT: St. George-Hyslop et al. FILING DATE: 6/29/01  
CONFIRMATION NO: 3866

**U.S. PATENT DOCUMENTS**

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>NAME</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>FILING DATE</u>
	1. 5,877,399	3/2/99	Hsiao et al.	800	2	6/17/96
	2. 6,037,521	3/14/00	Sato et al.	800	18	11/14/94
	3. 5,894,078	4/13/99	Nalbantoglu et al.	800	2	2/26/96
	4. 5,850,003	12/15/98	McLonogue et al.	800	2	1/22/97
	5. 5,898,094	4/27/99	Duff et al.	800	2	7/30/97
	6. 6,117,978	9/12/00	St.George-Hyslop et al.	530	350	7/29/98
	7. 5,612,486	3/18/97	McConlogue et al.	800	2	11/1/93

**FOREIGN PATENT DOCUMENTS**

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>TRANSLATION YES NO</u>
	8. WO 96/34099	10/31/96				

**OTHER REFERENCES****(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)****\*EXAMINER  
INITIALS**

9. Van Leuven, F. (2000) "Single and multiple transgenic mice as models for Alzheimer's Disease", Prog. Neurobiol., 61: 305-312
10. Sturchler-Pierrat, C. et al., (1997) "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology", Proc Natl Acad Sci USA 94(24), 13287-92
11. Hsia AY et al, (1999) "Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models", Proc Natl Acad Sci USA. 96,3228-33

**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

DOCKET NO.: 1034/1J800US1 SERIAL NO: 09/884,629  
APPLICANT: St. George-Hyslop et al. FILING DATE: 6/29/01  
CONFIRMATION NO: 3866

**\*EXAMINER  
INITIALS**

12. McGowan et al., (1999) "Amyloid Phenotype Characterization of Transgenic Mice Overexpressing both Mutant Amyloid Precursor Protein and Mutant Presenilin 1 Transgenes", Neurobiol. of Disease, 6:231-244
13. Holcomb L., Gordon MN., McGowan E., et al. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant *amyloid precursor protein* and *presenilin 1* transgenes", Nature Med., 4:97-100

EXAMINER: \_\_\_\_\_

DATE CONSIDERED: \_\_\_\_\_

**\*EXAMINER:**

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.